PReS13-SPK-1283: Pathogenesis, diagnosis and management of neuropsychiatric SLE
نویسندگان
چکیده
منابع مشابه
PReS13-SPK-1283: Pathogenesis, diagnosis and management of neuropsychiatric SLE
Neuropsychiatric (NP) manifestations pose diagnostic and therapeutic challenges in systemic lupus erythematosus (SLE). Less than one-third of these events can be directly attributed to SLE; accordingly attribution to SLE remains a considerable challenge. Increased generalized SLE disease activity or damage, previous or concurrent major neuropsychiatric SLE (NPSLE) events, and persistently posit...
متن کاملPReS13-SPK-1129: Biologic therapies in SLE
Biologic therapy has not made the breakthrough in the treatment of patients with systemic lupus erythematosus (SLE) that it has managed in patients with rheumatoid arthritis and psoriatic arthritis. However, there are distinct signs that this form of treatment is going to find a place in the pantheon of SLE therapy. Based on a better knowledge of the ethiopathogenesis of lupus drugs, which inte...
متن کاملPReS13-SPK-1469: Juvenile scleroderma
Juvenile localized scleroderma, also known as morphea, is the more frequent subtype of scleroderma in childhood. It comprises a group of distinct conditions which involve the skin and subcutaneous tissues. They range from very small plaques of fibrosis involving only the skin, to diseases which may cause significant functional and cosmetic deformity. The most widely used classification divides ...
متن کاملPReS13-SPK-1572: The therapy management of pain amplification syndrome
Pain syndromes often provide the clinician with the most complex challenges in understanding the condition as well as working out the maintaining factors and therefore how to support these patients back to function and recovery. These young people are often very disabled by these conditions and struggle to function in all aspects of their life including school and socially. The bio-psychosocial...
متن کاملPReS13-SPK-1240: New aspects on APS pathogenesis
Antiphospholipid antibodies (aPL) are both diagnostic markers for, and pathogenic drivers of, antiphospholipid syndrome (APS). Beta 2 glycoprotein I (Beta2GPI)dependent aPL, the most important subset, mediate different–and not necessarily alternative–thrombogenic mechanisms, mainly on the basis of their reactivity with Beta2GPI expressed on cells that participate in the coagulation cascade. In ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Rheumatology
سال: 2013
ISSN: 1546-0096
DOI: 10.1186/1546-0096-11-s2-i4